text:
1 from 5 interpreters in Peterborough is available for order
Order now, pay later with FREE order cancelation! No agent's markups.
$360.0/8 hoursdetails
Medical / Legal Interpreter in Cambridge. I hold a full DPSI (Diploma in Public Service Interpreting, Law Option). My areas of expertise include the following: Translation from French, German, Latin into Russian, from English into Russian both ways. Interpreting from English into Russian both ways, proofreading and transcription.


text:
If it Ain't Broke, Fix it Till it is!Opinion June 9, 2014
Opinion by George McClellan:Apparently that's the Obama administrations latent motto.Thanks Niki! It's like tinkering with a broken GM automobile. For example, if the Unaffordable, No Care Act, aka: Obamacare, isn't working at its very worst, then just tweak it til it does. He's even got some Republicans agreeing with him to fix it. Just listen to some of those loonies up there, on our side, wanting to correct the uncorrectable. They say we can "tweak this", "drop the other thing, but let's keep that, and the engine should start". No, No, No! That engine is already broke, irrevocably! It was made that way and no amount of spit and wire or tweaking is going to fix it. Even if it clanks along coughing and sputtering and blowing smoke… it's still broken! Dump it in the trash or sell it to the Chinese (they have lots of money) and let's move on.
How about America's foreign policy? Foreign policy reflects a country's goals and interests and ours wasn't broke! America was once "the shining city on the hill" that all people strived to emulate. Obama fixed it! Our foreign policy is now a collection of unachieved goals, humiliating defeats, unnecessary military deaths, and a predictable loss of trust by our allies, leaving them gasping in uncertainty over their own future prospects doubting America's commitment to back their play. Obama couldn't wait to cease our anti-terrorist war operations in Iraq, the "bad war", but he cranked up the Arab Spring fiasco. Libya wasn't leaderless and in chaos. It is now, and hundreds of wanna-be leaders are killing for the top job. Afghanistan, he said, was the "good war" that we needed to see through to the end. He tweaked that, didn't he? The end of the war is in site. We know the exact date, and while Obama believes he can unilaterally call the war to an end, the Taliban and al Qaida didn't get the memo. They're still at war and now we can expect that war to come here, not stay there. America's first line of defense, its wonderful military machine, is now a hollow shell of itself, because Obama fixed it.
The Bill of Rights are an annoyance to him because it doesn't comport to his socialist ideas of utopia. So, he's trying to fix the Bill of Rights. But our Bill of Rights has long been our established belief system, the ideals that made America exceptional above all others. He particularly wants to fix the second amendment. But it ain't broke, yet! He say's 'The people don't need it. Why should they? They have the government to protect them'. The nice thing about the 2nd amendment is that it won't be needed it until the government tries to take it away. Remember Fast and Furious? That was an exercise in tinkering with the 2nd amendment that killed many people in Mexico. I don't wonder that one day Mexico might not have Obama and Holder arrested for trial in the World Court for the many murders committed from their scheme.
Our American history ain't broke so let's fix it too. At a political fundraiser in Chicago last week, he stopped blaming George W. Bush for his problems. He now blames the Founding Fathers. Obama believes he is hindered in moving his socialist agenda forward because the Constitution requires that each State be represented by two Senators. "Obviously, the nature of the Senate means that California has the same number of seats as Wyoming. That puts us at a disadvantage." Whoa! Did you hear that? That can only be called "hutzpah". To whom was he speaking? The low information voters because they have been dumbed down by Liberalism.
Where do we begin? How do we even envision repairing the damage that Obama and the Progressives have done to our America? How do we start? Us kids from the 50's and 60's knew how to repair cars that were not running well. We knew that parts with oil or grease on them had to be kept out of the sand. Obama has thrown tons of sand in our mechanism and it needs flushing, desperately. It all needs to be replaced with the original. Remember, freedom is the goal, the Constitution is the way. Now, go get 'em! (7 June 2014).

subset: commoncrawl


text:
Hey girl- what's up?
Da f*ck were you thinking?
Like literally. How do you not see the symptoms of a man-child when they are staring you dumb in the face? He literally is 25 and funneling beer in his snapchat story. How on Earth did that not scream "hasn't left his college days behind"?
He was seeing you because he wants to relive those good old days in the basement of the Rugby House. You should've seen that coming when he made numerous comments about how he hated those "frat guys" but the guys on his team were his crew and how if he hadn't fractured his shoulder, he could have gone pro or taken them to nationals.
Come on.
You're not stupid. Stop acting stupid.
Also, stop dating pretty idiots. Sure, it was fun for a few months, but what lacks substance brings no worth to your life. And those boys lack so much substance.
Get your sh*t together girlfriend,
XO, Maz


text:
Food Lane will move its existing market in the Lehigh Shopping Center, Bethlehem, into the expanded former Acme Market building there, probably in October, Laneco Chairman Raymond Bartolacci said yesterday.
Construction has begun on a project doubling the size of the future Food Lane store to 38,400 square feet.
The Bethlehem Planning Commission approved plans for the building expansion in the center, at Union Boulevard and Pennsylvania Avenue, in January.


text:
Listing Provided Courtesy ofCentury 21 Agate Realty Tour
It's free with no obligation - cancel anytime
OCEANFRONT! THE ROAR OF THE SURF & THE SANDY BEACH BECKON YOU TO COME HOME! Beautiful & inviting with all the amenities 5bd/4.5ba, Granite, Tile, family room, large master suite w/custom bath, fireplace & slider to deck, 2nd master, crown moldings, walls of windows to take in the expansive views & OF deck w/hot tub. Quick easy access from deck to fantastic sandy beach where the Winchuck River meets the ocean! Truly a spectacular home!
Don't worry! We'll never spam you or sell your details. You can unsubscribe whenever you'd like.
Listing Courtesy ofCentury 21 Agate Realty


text:
Every year the southern city of China, Yulin celebrates the summer solstice with a festival that involves the slaughter and consumption of as many as 10,000 dogs. Many petitions have failed in the past but thanks to people taking real action, 100 dogs have been saved by a 65-year-old retired teacher. Her name is Yang Xiaoyun and she runs an animal ... Read More »
Tag Archives: woman
This Woman Lost Her Leg From Using a Tampon: Her Story Will Shock You
At 24, Lauren Wasser had the life. She was the 5'11" child of two models, with blond hair, blue eyes, and bone structure that looked like Santa Monica's androgynous answer to Lara Stone. She'd given up a full-ride basketball scholarship at a Division I school in order to pursue modeling—a career that started auspiciously when she was two months old ... Read More »
19 Awesome Inventions By Women Which Became Our Basic Needs
Necessity isn't the only mother of invention. Though it wasn't always easy to get patents or the credit they deserved, women are responsible for many items we use today. 1. THE PAPER BAG America got a brand new paper bag when cotton mill worker Margaret Knight invented a machine to make them with a flat square bottom in 1868. (Paper ... Read More »
45 Ridiculous Thoughts A Girl Has When He's Not Texting Her Back
It seems that the phone has become the most significant device of communication in most people's lives. So it's only fair to have something close of an anxiety attack when we can't reach another fellow human, when we can't text him/her, or she/he doesn't text back. source OMG, did I press send? I sure did, so he must be ignoring ... Read More »
Unwed Woman Takes Photos With Mannequin Family Over 14 Years
Ha ha! What kind of Woman would do such a thing? Crazy, nutter, psycho, weirdo, histrionic freak! Is that what comes to mind when you see these photos? If so, then you have proven my point. You've just judged a woman without knowing her. Don't worry, you're not alone. Most often a woman is defined by the relationship of Wife ... Read More »


text:
A lot of people in the geek community were genuinely saddened to hear that The Enderle Group lost their one (and only) client last year. Rob was one of the most genuinely amusing figures in the tech world – his "studies" were generally comedy gold – and he was handy, too: If you saw an article in the news that quoted a study by "The Enderle Group" you immediately knew that the reporter writing the piece was a know-nothing hack. It's rare to have such a cut-and-dried metric about anything these days.
So it was unfortunate for all of us when Microsoft terminated their contract with the Rob and his phantom group. Would we never again see quotes from some breathless study exploring the awesomeness of a company that just happened to be his client? Or better yet, a hand-wringing condemnation of a company or product that just happened to be a major competitor to his client?
Of course not. Guys like Rob are amazingly resilient. So it was not a huge surprise when The Enderle Group picked up a shiny new client in Research In Motion and wasted no time in getting to work.
Welcome back, Rob … we missed you.


text:
Enjoy the Weekend!
2 days ago
I was just scrolling by and to my surprise had an orgasm.
That bike is amazing. How much does that cost? I'm thinking about getting a fixie but i'm nervous about having the peddles still moving when i'm going down hill and what not...sorta scary.


text:
Reforming our nation's criminal justice system is critical to ending hunger and poverty in the United States. Families are directly impacted when loved ones are incarcerated, especially if they are serving long prison sentences.
But there is an opportunity to change this. The bipartisan Sentencing Reform Act of 2015 can reform our criminal justice system and give returning citizens a second chance. Your members of Congress need to hear from you that reforming our criminal justice system and ending mass incarceration must be a priority in 2018.
Tip: Personalized emails have the most impact. Add a note explaining why hunger is important to you.
If you take action and have not already registered, you will receive periodic updates and communications from Bread for the World.
Dear [decision maker],
Sincerely,[Your Name] [Your Address] [City, State ZIP]


text:
Card Workshop: Teresa's Card Classes DVDs
Viewer Comments
I really love the new cards, I do scrapbook pages also but now I am retired and can really get into the cards. Keep up the good work all. Thanks,
Yes, what an appropriate name - and what a start !! Amazing and wonderful !
These are some great CD's and the cards look like such fun to make and give. I'm excited to get these and put the ideas to use.
I am so excited for ne techniques and ideas for my cards.
How fun! You're always coming up with new & exciting. It's almost like Christmas! Thanks girls.
Paper Wishes Weekly Webisodes feature free scrapbooking video classes and card making video classes! Every week Paulette and Gail bring you new online scrapbooking or card making classes demonstrating the very latest paper craft and scrapbooking techniques. Each of our free card making and scrapbooking classes also gives you unique project ideas and tips from Paper Wishes' Design Team. Come back often so you don't miss any of the fun in our card making and scrapbooking classes! You are sure to be inspired! Also watch for our "Week of Webisodes" events where we feature new scrapbooking video classes daily!


text:
Will Groupon really boost your local business?
Editors Note: I stumbled upon this eye opening article about Groupon and how it is not necessarily the best thing for all businesses to use. It may just not live up to all the hype. Groupon seems very good initially, I mean who wouldnt want to have exposure to tens of thousands of local consumers who wait with baited breath each time they get an email from groupon. Problem is though, that there is a catch and sometimes that catch is not beneficial when you think about it and actually crunch the numbers. My boy scout troop runs a haunted house here in red oak and came to the same conclusion... even though it would increase our attendance significantly, it would ultimately cost us money to do it so we opted not to. Read this article (originally posted here) and see if you come to the same conclusion or not.
Groupon has been hailed as the new miracle advertising tool. It has also been accused of being a ruthless corporate giant, preying on the ignorance of small businesses.
Since its inception in November 2008, Groupon (think social media meets coupons) has transformed the way local businesses promote their products and services.
How does it work?
read the rest of the story on socialmediaexaminer.com. They wouldn't let us post the entire article here.
Leave a Reply
Blog Categories
- Blogs and Blogging
- Branding
- Custom Website
- Dallas Web Designer
- Funny Stuff
- Helpful Info
- Local Website Consultants
- Mobile Web and Smartpones
- Online Marketing
- Pursuing Excellence
- QR Codes
- Search Engine Optimization
- Security Alerts
- Selling
- Small Business Stuff
- Small Business Websites
- Social Networking
- Thumbtack Q&A Series
- Video
- World Wide Web
- Your Computer
- YWG Products & Services


text:
What would this week be without a picture of Madison in her carseat?? I have company coming today and I needed to run to the grocery store. I waited until the LAST possible time to go and of course it's just pouring today! Well no grocery store trip is complete without a balloon. Our Harris Teeter in NC gave just balloons, but the HEB here in Texas attach a sucker at the bottom (which I hate!). Madison knows it's there and I cannot deny her the sucker. I laughed out loud as I pulled into my drive way and looked back at Madison... yes, I am that anal to put a bib on her while she eats a sucker! Doesn't she just make you giggle out loud?!
Tuesday, March 16, 2010
HEB Sucker
Subscribe to: Post Comments (Atom)


text:
THR's Guider added to Peabody board
EmptyElizabeth Guider, editor of The Hollywood Reporter, has been tapped as a member of the board of the Peabody Awards and will participate in the selection process for winners in the 68th annual competition.
Guider is the first staffer at THR to serve on the 16-member board and will do so for three years.
Winners for outstanding achievement in electronic media — consisting of radio, television, cable and Web content aired in 2008 — will be unveiled April 1 ahead of the awards presentation May 18. (partialdiff)


text:
Stained Glass: Columbus, Ohio — Broad St. Presbyterian
Published by
I am a pianist, musician, music teacher, choir director, mother, wife, daughter, sister, cousin, sister-in-law, friend, neighbor. I enjoy music (of course!), quilting, sewing, beading, traveling, kayaking, camping, biking, hiking, gardening, knitting, scrapbooking, cooking, reading, poetry, drinking good coffee, and having fun with family and friends. NOTE -- Creative Commons License: All work of The Tromp Queen (quirkyjazz, aka Jill) is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License. View all posts by quirkyjazz


text:
- What: Guitar Hero: Van Halen
- Where: The Game Collection
- Current Price: £4.99
- Guitar Hero: Van Halen PS3 Price Comparison
It might actually be worth picking up a copy of Guitar Hero: Van Halen, just for the extra songs that it'll add to your virtual repertoire, now the price has come down to just below a fiver. You'll also save yourself about £3 on the next best offer coming in from Sendit. The set list is of course very Van Halen heavy, but you'll also find tracks by Foo Fighters, Weezer, The Offspring, Jimmy Eat World, and Killswitch Engage. Thanks to janner66 @ HUKD.


text:
It's no coincidence that there are far more cooking fires on Thanksgiving than on any other day. And as close as Christmas may be, Santa isn't known for giving out new houses.
That's why the National Fire Protection Association (NFPA) is warning Americans to stay attentive while they cook their holiday meals, despite the normal distractions.
And outside traditional Thanksgiving meal preparation, the organization recommends that consumers do not use outdoor gas-fueled turkey fryers themselves.
NFPA says there are three times as many home cooking fires on Thanksgiving as on any other day of the year. Turkey Day saw 1,370 fires in 2010 - a 219 percent increase over the daily average.
"Thanksgiving is a fun, festive holiday, but it's also very hectic," said Lorraine Carli, Vice President of Communications for NFPA.
"All the entertaining and distractions make it easy to forget about what's cooking on the stovetop."
Locally, Washington Township Fire Chief John Hoffman concurs.
"Every holiday season, especially around Thanksgiving and Christmas, we do seem to have an increase in cooking fires," Hoffman said.
He recalled a recent fire involving a turkey fryer.
"A couple of years back, we did have one that got out of hand and burnt up a home's siding," he said.
"With deep fryers, it's important to make sure the turkey is thawed," Hoffman pointed out. That's because water doesn't mix with cooking oil. And when a turkey isn't well-thawed, the results can be painful or deadly.
Hoffman said it's important to keep kids away from the fryer, and the fryer away from the home's siding. Homeowners shouldn't fry their turkeys on their decks either, he added.
NFPA offers some simple - but easily ignored tips - on Thanksgiving cooking, even without a fryer:
* Always remain in the kitchen while cooking. If you must leave the kitchen, even if only briefly, turn off the stove.
* Check food regularly as it cooks. Remain in the home and use a timer to remind you that you're cooking.
* Stay alert. If you're sleepy or have consumed alcohol, don't use the stove or stovetop.
* Keep items that can catch fire away from the stovetop. These include oven mitts, wooden utensils, food packaging, towels, curtains and other items.
If a fire does occur, the NFPA says you should:
* Get out of the house, closing the door behind you as you leave to help contain the fire.
* Call 911 or the local emergency number from outside the house.
* If you try to fight the fire, make sure others are leaving and that you have a clear path out of the home. Also be sure someone has called the fire department.
* A lid should be kept nearby to smother any small grease fires. Smother a fire by sliding the lid over the pan, and turn off the stovetop. Leave the pan covered until it is completely cooled.
* For an oven fire, turn off the heat and keep the oven door closed.
As for do-it-yourself frying on Thanksgiving, NFPA isn't crazy about the idea. They use lots of oil, the group says on its website, "and units currently available for home use pose a significant danger that hot oil will be released at some point during the cooking process."
The hot liquid can very overflow and produce flames that cause serious burns and even destroy a home.
NFPA recommends Thanksgiving revelers seeking fried turkey "seek out professional establishments, such as grocery stores, specialty food retailers and restaurants for the preparation of the dish, or consider a new type of oil-less turkey fryer."
Follow @gctimesonline "


text:
Pleural Mesothelioma: Diagnostic Problems and Evaluation of Prognostic Factors
- Egbert Samson O'Connor'
- 3 years ago
- Views:
1 Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 4, December: , 2006 Pleural Mesothelioma: Diagnostic Problems and Evaluation of Prognostic Factors HODA M. ISMAIL, M.D.*; MOHAMED AKRAM A. NOUH, M.D.*; IMAN L. ABULKHEIR, M.D.*; ABD EL-RAHMAN M. ABD EL-RAHMAN, M.D.** and HASSAN N. TAWFIK, Ph.D.* The Departments of Pathology* and Surgical Oncology**, National Cancer Institute, Cairo University. ABSTRACT Background: Malignant pleural mesothelioma (MPM) in Egypt is mainly attributed to an environmental origin i.e exposure to asbestos, with a high incidence in women and young adults. Immunohistochemistry and ultrastructural features aid in the diagnosis. The p27kip1 is a kinase inhibitor protein acting as a cell cycle regulator and a putative tumor suppressor gene playing a critical role in the pathogenesis of several human neoplasms. Aim: A clinicopathologic, immunohistochemical and ultrastructural study of mesothelioma in Egyptian patients, with identification of different prognostic factors. Material and Methods: Sixty-one cases of MPM were collected from the department of pathology at the NCI, Cairo. Cases were stained by monoclonal antibodies against CK5/6, calretinin, vimentin, CD15, CEA and p27. Results: More than half (57.4%) of the patients were residents in endemic areas; 50.8% were of epithelioid type. CK5/6 was positive in 45 (73.8%) cases, 39 (63.9%) cases were positive for vimentin, 49 (80.3%) cases were positive for calretinin. One case showed a focal weak positive reaction to CD15. None of the cases stained for CEA. There was a statistically significant relation between p27 expression and the histopathologic type (p=0.02) between overall survival and age (p=0.01), histopathologic type (p=0.02) and stage (p=0.006). Conclusion: MPM is an increasing disaster in Egypt which is underestimated and neglected. A panel of immunohistochemical markers should be used for proper evaluation. p27 has proven to be a potential biologic prognostic marker for mesothelioma and more studies as regard its significance are recommended on a larger number. Key Words: Mesothelioma Asbestos CK5 / 6 Calretinin p27. INTRODUCTION Malignant pleural mesothelioma (MPM) is an uncommon neoplasm, yet is the most frequent Correspondence: Dr Hoda Ismail, 17 El Mathaf El Zeraie St., neoplasm affecting the pleura and remains a major health threat for many years to come. Although the causation by asbestos is firmly established since more than 50 years, in many world regions the use of this dangerous carcinogen peaked between 1970 and 1990 [1]. MPM has a progressively downhill course with a median survival in the order of 10 months [2]. Cytokeratin (CK) filaments are the intermediate filaments forming the skeleton of epithelial cells, providing support to maintain cell integrity and the structure of epithelial tissues. Human epithelia can present 20 different types of CKs [3]. CK5/6 is one of the positive markers for mesothelioma with high sensitivity (80-100%) and sufficient specificity for practical use in distinguishing it from metastatic adenocarcinomas [4,5]. Calretinin is a 29 KDa protein that is a member of a large family of calcium-binding proteins. Several studies have indicated the importance of calretinin as a positive marker for the diagnosis of mesothelioma [6-8]. Leu- M1 is one of a large group of antibodies against an antigen defined by the cluster designation group 15 (CD15) [9]. Leu-M1 is considered a highly specific marker for separating adenocarcinomas from mesotheliomas; however, its sensitivity is rather low, especially when compared with other negative mesothelioma markers [10]. p27 is a cyclin dependent kinase inhibitor which blocks the cell cycle and prevents its progression from G1 to S phase.reduced expression of p27 has been correlated with an adverse clinical outcome of a number of neoplasms including MPM [11]. The identifiaction 303
2 304 Pleural Mesothelioma: Diagnostic Problems & Evaluation of prognostic factors is important to properly counsel patients and their families, monitor treatment options and guide the development of novel therapies [2]. The aim of this work was to study the clinicopathologic features and immunoprofile, as well as to identify the prognostic factors, of MPM in Egyptian patients. MATERIAL AND METHODS Patients and samples: Sixty-one cases of MPM were collected from the department of pathology at The National Cancer Institute, Cairo University, from January 2000 to December Only patients with clear-cut clinicopathologic diagnosis of malignant mesothelioma and adequate surgical and biopsy specimens were included in the study. The ages of the patients ranged from 20 to 80 years. The patients were asked about their residence to identify areas with endemic asbestos exposure, e.g. Shobra El-Khema, Helwan and El-Hawamdia. The histopathologic type of MPM was defined according to the morphologic criteria of the WHO classification [1]. Staging was performed according to the staging system provided by the UICC [12]. Survival was taken as the duration between histologic diagnosis of MPM and date of death or last follow-up. Follow-up data were available for 51 cases only. Methods: Immunohistochemistry: Six unstained positively charged slides were prepared from each paraffin block for immunostaining with the following primary antibodies: CK5/6 (Lab Vision, dilution 1:50), calretinin (Dako, dilution 1:50), p27 (Dako, dilution 1:25), vimentin (Dako), CEA (Dako) and CD15 (Dako), the latter 3 antibodies were ready to use. Slides were deparaffinized in xylene twice for 10min, rehydrated through graded ethanol to distilled water, incubated for 15min with 3% hydrogen peroxidase to inhibit endogenous peroxidase activity, and then heated in 0.01mol/l citrate buffer (ph6.0) in a microwave oven for 5min at 100ºC for antigen retrieval. After cooling down to room temperature for 30min, the sections were incubated for 15min in a blocking solution containing 10% normal goat serum in PBS. Detection was by Biotin-Streptavidin Amplified (B-SA) system with diaminobenzidine chromogen as in routine protocol. Meyer s hematoxylin was used for counter staining. The slides were then dehydrated in increasing grades of ethanol, cleared in xylene and mounted. Positive controls were performed by concomitant application of the antibody to tissues known to be positive for each marker. Criteria for marker evaluation: Cytokeratin 5/6 positivity was encountered when diffuse cytoplasmic staining was observed with occasional perinuclear enhancement. Cases were considered positive for calretinin if finely granular cytoplasmic and nuclear immunostaining was recognized [6]. Cases were considered vimentin positive when diffuse cytoplasmic staining was encountered [9]. Immunopositivity for CEA was considered with diffuse cytoplasmic staining with occasional membrane enhancement [13]. CD15 immunopositivity was considered when there was diffuse or focal, finely to coarsely granular, predominantly cytoplasmic, immuoreactivity [9]. The percentage of tumor nuclei expressing p27 was determined by counting 1000 cells per slide. Nuclear staining only was considered positive [2]. Statistical analysis: SPSS version 12 was used for data analysis. ANOVA (non parametric) was used for comparisons of the means of more than 2 independent groups. Chi-square and Fisher's exact tested proportion independence. Kaplan Meier's method estimated overall survival. Log rank test compared survival curves. Cox-regression analysis was used to calculate Hazard ratio (odds ratio) and to show independent variables affecting overall survival. Significance level 0.05 was used throughout all statistical tests in the study [14]. RESULTS The mean age of the studied patients was 47.2 years, ranging from 20 to 80 years. Thirty seven cases were males (60.7%), and 24 (39.3%) cases were females. Thirty five (57.4%) cases were resident in endemic areas (Shobra El- Khema, Helwan, and El-Hawamdia), 10 (16.4%) cases were resident in non endemic areas, and 16 (26.2%) cases could not be traced according
3 Hoda M. Ismail, et al. 305 to habitat. Twenty four (39.3%) patients were subjected to open surgical biopsy, 2 (3.3%) patients underwent decortication and 35 (57.4%) patients underwent pleuropneumonectomy. Histopathologic type of MPM was defined according to morphologic criteria of the WHO classification [1]. Thirty one (50.8%) cases were of epithelioid type, 21 (34.4%) cases were of biphasic type, and 9 (14.8%) cases were of sarcomatoid type. Staging was performed according to the staging system provided by UICC [12]. Twenty one (34.4%) cases were in stage IV, 29 (47.6%) were in stage III and 11(18%) cases were in stage II. Immunohistochemical results: Fourty-five (73.8%) cases were positive for cytokeratin 5/6 (Fig. 1), 25 (25/31) cases were of epithelioid type, constituting 80.6% of epithelioid cases and 55.6% of all cases. Fourteen (14/21) cases of the biphasic type and 6 (6/9) cases of the sarcomatoid type were positive for CK 5/6. Fourty nine (80.3%) cases were positive for calretinin, 28 (28/31) cases were of epithelioid type constituting 90.3% of all epithelioid cases and 57.1% of all cases. Seventeen (17/21) cases of the biphasic type and 4 (4/9) cases of the sarcomatoid type were positive for calretinin (Fig. 2). Thirty-nine (63.9%) cases were positive for vimentin, 9 cases were of epithelioid type constituting 29% of all epithelioid cases and 23.1% of all cases. All 21 cases of the biphasic type as well as all the 9 cases of sarcomatoid type were positive for vimentin. All 61 cases were negative for CEA. Only one epithelioid case was focally and weakly positive for CD15 (1.6%). Regarding p27, the median percentage among all examined cases was 1.6% ranging from 0-70%. As regards epithelioid mesothelioma, the median percentage was 2.2 ranging from 0-34%, while, in biphasic mesothelioma (Fig. 3), the median percentage was 0.3 ranging from 0-8.1% and in sarcomatoid mesothelioma, the median percentage was 0 ranging from 0-70%. The relation between median percentage of p27 and histopathologic type recorded a highly statistically significant relationship; p= A level of 10% was taken as a convenient cut-off point [15], so that those recording less than or equal to 10% positive cells for p27 were considered low expressors, while those expressing more than 10% positive cells were considered high expressors. Most of the epithelioid cases were high expressors. A significant relation was obtained when comparing p27 score at 10% level with the pathologic type (p=0.02) (Table 1). Survival analysis: The minimum follow-up period was 2 years, while the maximum was 5 years. Overall survival of the cases ranged from one month to months (median: 5 months). A median survival of 4.13 months was observed in the epithelioid type, 9.63 months in the biphasic and 3 months in the sarcomatoid type. A statistically significant relation was detected on comparing overall survival and histopathologic type, recording a p-value of 0.025, (Fig. 4). Pair wise comparison showed that the difference between survival was the greatest between biphasic and sarcomatoid types, recording a highly significant statistical relation (p=0.004). A statistically significant relation was recorded between age and survival (Fig. 5); patients less than or equal 45 years showed a median survival of 8 months, while those older than 45 years had a median survival of 2.47 months (p=0.01). Although median survival in males (3.6 months) was much lower than females (8.43 months), the difference did not reach statistical significance (p=0.21). A highly statistically significant relation was obtained on comparing survival of patients in stage II and III (median survival of 8 months) to that of patients in stage IV (median survival of 2.47 months), recording a p value of (Fig. 6). As regards p27, despite the obvious trend for longer survival (8.47 months) in the high expressor group than low expressor group (4.40 months), this difference was statistically insignificant (p=0.2). Multivariate analysis of different clinicopathologic parameters and p27 immunostaining revealed that both age and stage were the only independent prognostic factors affecting survival in patients with MPM (Table 2). Table (1): Expression of p27 in relationto to different histologic types of mesothelioma. Histologic type Epithelioid Biphasic Sarcomatoid Total *p= No. of cases **p=0.02. p27%* Median (range) (0-34) (0-8.1) (0-70) (0-70) p27 Overexpression (>10%)** No. %
4 306 Pleural Mesothelioma: Diagnostic Problems & Evaluation 1.0 Variable B SE OR (95% CI) p value 0.8 Age >45 Stage IV ( ) 2.7 ( ) B = Regression coefficient. SE = Standard error of B. OR = Odds ratio. CI = Confidence interval. Cum survival Table (2): Cox regression analysis for overall survival in relation to age and stage. N= p = Epithelioid 0.2 Sarcomatoid Biphasic OS (months) Fig. (4): Median survival among various types of malignant mesothelioma Cum survival Fig. (1): Epithelioid mesothelioma positive for CK5/6 with perinuclear enhancement (x400). N= p= Y 45Y OS (months) Fig. (5): Survival in relation to age. Fig. (2): Biphasic mesothelioma, both components are positive for calretinin (x100). 1.0 N=51 Cum survival p= II & III IV Fig. (3): Biphasic mesothelioma with p27 positive epithelioid & sarcomatoid components (x400) OS (months) Fig. (6): Survival in relation to stage.
5 Hoda M. Ismail, et al. 307 DISCUSSION Malignant mesothelioma remains a highly lethal cancer. Recent advances in both surgical and medical therapy have improved survival, but the treatments remain toxic and the selection of appropriate patients for these therapies is difficult [16]. Mesothelioma in Egypt is mainly attributed to an environmental origin i.e exposure to asbestos, with a high incidence in women and young adults. The incidence of MPM is rising in Egypt [17]. In our study, the mean age of patients was 47.2 years and the median was 45 years, ranging from 20 to 80 years with a male to female ratio 1.5:1. These results lie in accordance with those obtained by El-Shafiey [18] who recorded a mean age of 47.4 years ranging from years and M:F ratio 1.7:1, as well as the results obtained by Abou Elkasem [19] who recorded a median age of 46 years and M:F1.4:1. In Western studies, the recorded median age was so much higher ranging from 60 to 69 years and M:F ratio higher than 10:1 [2,20,21]. The lower figures obtained by our study could be explained by the fact that most of our patients live in endemic areas, so the chance of exposure among both sexes is nearly equal with a slight increase in males due to their outdoor activities most of the time in the vicinity of the asbestos plants and due to occupational hazards. In our study, 77.8% of patients with known residence live in endemic areas (Shobra El- Khema, Helwan, and El-Hawamdia), reflecting to some extent also the percentage of asbestos exposure. Asbestos exposure in mesothelioma of 67%, 75.5% and 80 were reported in other studies [19,22,23]. This observation was properly analyzed by Testa and colleagues [22], who reported that approximately 80% of mesotheliomas were associated with asbestos exposure and that finding established an indisputable link between asbestos and mesothelioma. According to the histopathologic type, most of our cases were of the epithelioid type (50.8%), followed by the mixed type (34.4%) and the sarcomatoid type (14.8%). These results lie in accordance with other studies reporting highest frequency for epithelioid type and lowest for sarcomatoid type [2,19,23]. In our study, the most recent TNM classification system was adopted [12] and supported by proper accurate histopathologic evaluation, 18% of our cases were of stage II, 47.6% were of stage III, and 34.4% were of stage IV. None of our studied cases were of stage I, a finding which may highlight the aggression of the disease and the late presentation among Egyptian patients. Abou Elkasem [19] staged MPM cases according to the International Mesothelioma Interest Group (IMIG) staging system [24], with differences between preoperative and postoperative staging. Preoperative staging included 8 cases of stage I, 13 cases of stage II, and 1 case of stage III, while post operative staging included 3 cases of stage I, 5 cases of stage II, and 14 cases of stage III. This difference underlines the importance of the histopathology in identifying different categories of the TNM staging system. When the Butchart classification system [25] was adopted, stage I was reported in 35.1%, 52.5% and 66.9% of cases in different studies [18,21,23]. The high percentage of stage I was probably an overestimation because of the inadequacy of the classification system, a debate which was highlighted by Boutin and coworkers [23] who reported median survival for Butchart Stages I and II as 13.4 and 9.4 months, respectively. This slight difference underlined the limitations of this classification. In our study, 73.8% cases were positive for CK5/6, including 80.6% of epithelioid mesothelioma, 66.7% of biphasic mesothelioma, in which 10 cases showed positivity in both components, while 4 cases showed positivity in the epithelioid component only. In sarcomatoid mesothelioma 66.7% of the cases were positive. In other studies, CK5/6 was reported in % of cases of mesothelioma [4,10,13], indicating that CK5/6 is one of the most sensitive and specific available markers of malignant mesothelioma. It has been concluded that CK5/6 was diagnostically useful in distinguishing sarcomatoid mesotheliomas from most sarcomas and that positive staining with any antimesothelial antibody in conjugation with cytokeratin would favor the diagnosis of mesothelioma over spindle cell carcinoma [26]. Calretinin was positive in 80.3% of our cases, including 90.3% epithelioid mesothelioma, 44.4% sarcomatoid mesothelioma, and 81% mixed mesothelioma. The reaction was both
6 308 Pleural Mesothelioma: Diagnostic Problems & Evaluation nuclear and cytoplasmic. Kayser et al. [27] reported reactivity for calretinin in 82.2% of malignant mesotheliomas, including 84.8% epithelioid mesotheliomas, 75% mixed mesotheliomas, and 57% sarcomatoid mesotheliomas. They recorded a sensitivity of 81% and a specificity of 86% in distinguishing mesothelioma from metastatic carcinoma in the pleura. Comin et al. [7] concluded that calretinin seemed to be the most sensitive (100%) and specific (91.3%) mesothelioma marker. Moreover, the staining pattern for calretinin seemed to be highly specific (100%) in differentiating mesothelioma from lung adenocarcinoma because the former always showed nuclear and cytoplasmic staining, whereas the latter was either negative or showed only cytoplasmic staining. Ordonez [8] recorded reactivity for calretinin in 100% of epithelioid mesothelioma and only in 8% of lung adenocarcinoma. He concluded that calretinin is one of the best positive markers for differentiating epithelioid malignant mesothelioma from pulmonary adenocarcinoma. In accordance with our results on sarcomatoid mesothelioma, both nuclear and cytoplasmic expression for calretinin was obtained in 39% of sarcomatoid mesotheliomas with no expression in sarcomas or sarcomatoid carcinomas examined [26]. From these results, it is worth mentioning that although calretinin was not particularly sensitive for sarcomatoid mesothelioma, its specificity was 100%. Others concluded that although calretinin appeared one of the most useful markers for differentiating sarcomatoid mesothelioma from sarcoma, it was of no value in differentiating sarcomatoid mesothelioma from sarcomatoid carcinoma [28]. In our study, we reported vimentin positivity in 63.9% of the cases, including all biphasic and sarcomatoid cases and 29% of the epithelioid type. It is noteworthy to mention that coexpression of vimentin and CK5/6 was detected in 44.3%, thus confirming the value of coexpression of vimentin and CK5/6. Wick et al. [29] detected vimentin in 41% of epithelioid mesotheliomas in comparison to 17% of pulmonary adenocarcinomas Mayall and colleagues [30] identified vimentin in 54% and 74% of epithelioid and mixed mesotheliomas, respectively, and in 87% of sarcomatoid mesotheliomas. The variability in immunoreactivity for vimentin can be attributed to; first: Differences in tissue fixation [31] and second: The antibodies employed [5]. Kayser et al. [27] reported positivity for vimentin in 83% of malignant mesotheliomas, including 80% of epithelioid mesothelioma as well as 100% of sarcomatoid and biphasic mesothelioma, recording sensitivity of 82% and specificity of 52% in distinguishing mesothelioma from metastatic carcinoma in the pleura. None of our cases stained for CEA, while only one case of the epithelioid type showed a focal and weak positive reaction to CD15. It has been recommended that anti-cea and CD15 should always be included in the panel of antibodies used for immunohistochemical diagnosis of mesothelioma, since CD15 and CEA were the most specific for separating mesothelioma from adenocarcinoma [7]. As regards CEA, conflicting results have been reported from different series, recording CEA positivity in 15% to 45% of mesotheliomas and 100% to as few as 25% in adenocarcinomas. These discrepancies are believed to be attributable to different sensitivities and specificities of the different antibodies used. At present, this problem is not so much encountered as there are several anti- CEA monoclonal antibodies that do not stain mesotheliomas but do react with most adenocarcinomas [10]. A median survival ranging from 4 to 14.3 months in either untreated or treated patients was reported in MPM [19,32]. In our study, the median survival was as low as 5 months and ranged from one month to months, pointing strongly to the aggression of the disease among our studied cases of Egyptian patients. We found a statistically significant correlation between overall survival and age (p=0.01). Moreover, by Cox regression analysis, age was proved to be an independent prognostic factor (p=0.004). It has been reported that the best survival is associated with young age [33,34]; yet, others did not find any correlation [19,23]. In our study, there was an obvious trend for female patients to have a better survival than males, however, the difference did not reach the point of statistical significance. Edwards et al. [35] succeeded in detecting a statistically significant correlation confirming the association between poor prognosis and male gender. There was a statistically significant relation between the histopathologic type and survival (p=0.025) observed in our cases. It is noteworthy to men-
7 Hoda M. Ismail, et al. 309 tion that pair wise comparison has identified that the great difference between survivals among histopathologic types was estimated when comparing patients with mixed mesothelioma to those with sarcomatoid mesothelioma (p=0.004). A highly significant statistical relationship between histopathologic type and survival (p=0.001), with the best survival obtained in patients with the epithelioid and mixed types, was recorded [21]. Patients with the epithelioid type were categorized as long-term survival group [36]. In our study, there was a highly statistically significant relationship between survival and stage of malignant mesothelioma (p=0.006). Moreover, stage was proved to be an independent prognostic factor when subjected to Cox regression analysis (p= 0.002). In accordance with our results, Abou ElKasem [19] reported a statistically significant relationship between survival and stage (p=0.02). In our study, the median survival of low expressors ( 10%) of p27 was 4.40 months, while high expressors (>10%) had a median survival of 8.47 months. Inspite of this obvious trend for the high expressor group to live more, this relationship did not reach the level of statistical significance, most probably due to small sample number. There was a highly statistically significant relation between p27 expression and histopathologic type (p=0.004). The median percentage of p27 immunoreactivity was higher in the epithelioid type in comparison to the biphasic and sarcomatoid types. This statistically significant relation was also obtained when comparison between p27 and histopathologic type was done at the level of 10% as a cut-off point (p=0.02). It has been reported that low p27 expression was associated with a statistically significant decrease in survival, however, this observation showed border-line significance in the multivariate analysis [15]. Others also reported that alterations in cell cycle control proteins such as p16, p21, and p27 also offer information on prognosis and represent potential targets for therapy [16]. Conclusion: MPM is an increasing disaster in Egypt which is underestimated and neglected. A panel of immunohistochemical markers should be used for proper evaluation. p27 has proven to be a potential biologic prognostic marker for mesothelioma and more studies as regards its significance are recommended on a larger number of cases. REFERENCES 1- Churg A, Roggli V, Galateau-Salle F, Cage PHT, Gibbs AR, Haselton PHS et al. Tumor of the pleura. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). Pathology and Genetics. Tumors of the Lung, Pleura, Thymus, and Heart World Health Organization. IARC Lyon France. 2004, pp Beer TW, Shepherd P, Pullinger NC. p27 immunostainig is related to prognosis in malignant mesothelioma. Histopathol. 2001, 38: Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: Strategies, applications and limitations. Lab Invest. 1985, 52 (3): Clover J, Oates J, Edwards C. Anticytokeratin 5/6: A positive marker for epithelioid mesothelioma. Histopathol. 1997, 31: Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998, 22: Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, Viale G. Calretinin: A novel immunohistochemical marker for mesothelioma. Am J Surg Pathol. 1996, 20: Comin CE, Luca N, Vieri B, Paqlierani M, Dini S. Calretinin, Thrombomodulin, CEA, and CD15: A useful combination of immunohistochemical markers for differentiating pleural epithelioid mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001, 32: Ordonez NG. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003, 27 (8): Battifora H, McCaughey WTE. Tumors of the serosal membranes. In HartmannWH (ed). Atlas of Tumor Pathology. Third series. Fascicle 15. Washington, D.C. Armed Forces Institute of Pathology, Ordonez NG. Immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol. 1999, 30: Lloyd RV, Erickson AL, Jin L, Kulig E, Oian X, Cheville JS. p27 kip1 : A multifunctional cyclindependent kinase inhibitor with prognostic significance in human cancer. Am J Pathol. 1999, 154: International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. 6 th ed. Wiley and Sons: New York Carella R, Delionardi G, D'Errico A, Salemo A, Egarter-Vigl E, Seebacher C. Immunohistochemical
8 310 Pleural Mesothelioma: Diagnostic Problems & Evaluation panel for differentiating epithelial malignant mesothelioma from lung adenocarcinoma. Am J Surg Pathol. 2001, 25: Riffenburgh RH. (ed) Statistics in medicine. 2 nd edition. Amsterdam, Elsevier Academic Press Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, et al. Prognostic significance of cyclooxygenase 2 and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004, 59 (6): Kumar P, Kratzle RA. Molecular prognostic markers in malignant mesothelioma. Lung Cancer. 2005, 49 (Suppl 1): S53-S Gaafar RM, Eldin NH. Epidemic of mesothelioma in Egypt. Lung Cancer. 2005, 49: El-Shafiey MM. Evaluation of combined surgery and radiotherapy in treatment of stage I malignant pleural mesothelioma, MD thesis. Surgical Oncology Department. National Cancer Institute, Cairo University, Abou Elkasem FM. Management of Malignant Pleural Mesothelioma with Special Emphasis on Biological Markers. MD Thesis. Medical Oncology Departement. National Cancer Institute. Cairo University, Vogelzang NJ, Schultz SM, Iannuci AM, Kennedy BJ Malignant mesothelioma: The University of Minnesota experience. Cancer. 1984, 53: De Pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer. 1993, 72: Testa JR, Pass HI, Carbone M. Molecular biology of mesothelioma, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott. 2000, pp: Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 conecutive patients. Cancer. 1993, 72: Rusch VW. Clinical features and current treatment of diffuse malignant mesothelioma. Lung Cancer. 1995, 12 (Suppl2): S Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura (experience with 29 patients). Thorax. 1976, 31: Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Antimesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathol. 2000, 37: Kayser K, Bohm G, Blum S, Beyer M, Zink S, Andre S, Gabius HJ. Glyco-and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. J Pathol. 2001, 193: Lucas DR, Pass HA, Madan SK, Adsay NV, Wali A, Tabaczka P, Lonardo F. Sarcomatoid mesothelioma and its histological mimics: A comparative immunohistochemical study. Histopathol. 2003, 42: Wick MR, Loy T, Mills SE, Legier JF, Manivel JC. Malignant epithelioid mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol. 1990, 21: Mayall FG, Goddard H, Gibbs AR. Intermediate filament expression in mesotheliomas: Leimyoid mesotheliomas are not uncommon. Histopathol. 1992, 21: Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol. 1985, 9: Comin CE, Anichini C, Boddi V, Novelli L, Dini S. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathol. 2000, 36: Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and leukemia Group B. Chest. 1998, 113: Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg. 1999, 68: Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring system. Thorax. 2000, 55: Bongiovanni M, Cassoni R, De Giuli P, Viberti L, Cappia S, Ivaldi C, et al. p27 immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer. 2001, 92:
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology ImmunohistochemicalMore information
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma MICHAEL G. HURTUK and MICHELE CARBONE Cardinal Bernadin Cancer Center, Cancer Immunology Program, Department of Pathology,More information
20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,More information
Abstract. Introduction. Material and Methods
Original Article Expression of Mesothelial Markers in Malignant Mesotheliomas: an Immunohistochemical Evaluation of 173 Cases I.N. Soomro, R. Oliveira*, J. Ronan, Z. R. Chaudry, J. Johnson Department ofMore information
بسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesotheliomaMore information
Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most areMore information
Diagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 email@example.com information
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,More information
Case of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendixMore information
The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,More information
Practical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.More information
L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,More information
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on AppliedMore information
Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.More information
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,More information
Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia CaseMore information
Malignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIGMore information
A 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, whichMore information
Product Datasheet and Instructions for Use
Product Code: MP-092-CR01 (0.1ml concentrate) MP-092-CR05 (0.5ml concentrate) MP-092-CR1 (1ml concentrate) MP-092-PR6 (6ml RTU) Product Description: Calretinin Concentrated and Prediluted Polyclonal AntibodyMore information
Original Article Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry
Pathology International 2008; 58: 75 83 doi:10.1111/j.1440-1827.2007.02193.x Original Article Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistryMore information
Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.
Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging systemMore information
Diagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University HospitalMore information
Rare Thoracic Tumours
Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPCMore information
Recommendations for the Reporting of Pleural Mesothelioma
Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reportsMore information
The develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymalMore information
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30More information
DATA SUPPLEMENT EXPRESSION OF TUMOR-DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS IS ASSOCIATED WITH OUTCOME IN EARLY SQUAMOUS CELL CARCINOMA OF THE LUNG María J. Pajares et al. PATIENTSMore information
Testing of Kappa and Lambda immunoglobulin light chain antibodies kappa DB037-1 and lambda DB039-1 light chain antibodies, developed by DB Biotech
Testing of Kappa and Lambda immunoglobulin light chain antibodies r. Marian Švajdler, Louis Pasteur University Hospital, epartment of Pathology Košice, Slovakia In this retrospective study, we have testedMore information
Mesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latencyMore information
Clinicopathological Study on Malignant Pleural Mesotheliomas
Table of Contents Clinicopathological Study on Malignant Pleural Mesotheliomas PL-4-03 Kenzo Hiroshima Kenzo Hiroshima 1, Akira Iyota 1, Kiyoshi Sibuya 1, Toshikazu Yusa 2, Takehiko Fujisawa 1 and YukioMore information
Notice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada email@example.com Notice of Faculty Disclosure In accordance withMore information
Malignant Pleural Mesothelioma in Singapore
RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods andMore information
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologicMore information
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-BronMore information
prognostic scoring systems. We
Thorax 2000;55:731 735 731 Original articles Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems J G Edwards, K R Abrams, J N Leverment,More information
Pleural Mesothelioma: An Institutional Experience of 66 Cases
The Korean Journal of Pathology 2014; 48: 91-99 ORIGINAL ARTICLE Pleural Mesothelioma: An Institutional Experience of 66 Cases Soomin Ahn In Ho Choi Joungho Han Jhingook Kim 1 Myung-Ju Ahn 2 DepartmentsMore information
HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: email@example.com 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma fromMore information
Short title running head: Immunohistochemistry of mesothelioma Authors running head: K. Kushitani et al. Correspondence: Kouki Inai, MD, PhD, Department of Pathology, Postgraduate School of BiomedicalMore information
264 Diagnostic Cytopathology, Vol 38, No 4 ' 2010 WILEY-LISS, INC.
Podoplanin Is a Useful Marker for Identifying Mesothelioma in Malignant Effusions Atef Hanna, M.D., Ph.D., 1 Yijun Pang, M.D., Ph.D., 1 Carlos W. M. Bedrossian, M.D., 2 Annika Dejmek, M.D., Ph.D., 3 andMore information
Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation InsidiousMore information
Survey of Mesothelioma Associated with Asbestos Exposure in Japan
The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristicsMore information
A new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; email@example.com (2) StevenMore information
The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura
Strana 1010 VOJNOSANITETSKI PREGLED Vojnosanit Pregl 2013; 70(11): 1010 1014. ORIGINAL ARTICLE UDC: 616.25-006-07 DOI: 10.2298/VSP110527025P The role of immunohistochemical evaluation in the diagnosisMore information
Distinguishing benign from malignant mesothelial
ORIGINAL ARTICLE IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations Anna F. Lee, MDCM, PhD,*w Allen M. Gown, MD,wz and Andrew Churg, MD*w Abstract:More information
Product Datasheet and Instructions for Use
Product Code: MP-378-CMK01 (0.1ml conc) MP-378-CMK05 (0.5ml conc) MP-378-PM6 (6ml RTU) Product Description: CD141 (Thrombomodulin) Concentrated and Prediluted Monoclonal Antibody Control Number: 901-378-071709More information
Case Report Epithelioid malignant mesothelioma presenting with features of gastric tumor in a child
Int J Clin Exp Pathol 2014;7(5):2636-2640 www.ijcep.com /ISSN:1936-2625/IJCEP0000187 Case Report Epithelioid malignant mesothelioma presenting with features of gastric tumor in a child Qihan You 1, JingMore information
HER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factorMore information
The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions
The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions Farnaz Hasteh, MD 1 ; Grace Y. Lin, MD, PhD 1 ; Noel Weidner, MD 1 ; and ClaireMore information
Characteristics of Malignant Pleural Mesothelioma in Women
Characteristics of Malignant Pleural Mesothelioma in Women Andrea S. Wolf, MD, MPH, William G. Richards, PhD, Tamara R. Tilleman, MD, PhD, Lucian Chirieac, MD, Shelley Hurwitz, PhD, Raphael Bueno, MD,More information
Ovarian tumors Ancillary methods
Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division ofMore information
Carcinosarcoma of the Ovary
Carcinosarcoma of the Ovary A Rare Finding Presented By: Kathryn Kiely Anisa I. Kanbour School of Cytotechnology of the University of Pittsburgh Medical Center Pittsburgh, PA Patient History 55 year oldMore information
Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!
Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor ofMore information
Subtle mediastinal pleural thickening on computerised tomography as a predictor of mesothelioma
Subtle mediastinal pleural thickening on computerised tomography as a predictor of mesothelioma Poster No.: C-1794 Congress: ECR 2011 Type: Scientific Exhibit Authors: A. Roy, S. ellis, T. Iyngkaran ;More information
Like diffuse malignant mesothelioma (DMM), metastatic
Expression of Renal Cell Carcinoma Associated Markers Erythropoietin, CD10, and Renal Cell Carcinoma Marker in Diffuse Malignant Mesothelioma and Metastatic Renal Cell Carcinoma Kelly J. Butnor, MD; AndrewMore information
3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, whichMore information
No Difference Between Mesothelioma and Pulmonary and Nonpulmonary Adenocarcinoma DO NOT DUPLICATE. Malignancy is a common cause of effusions of the
NONGYNECOLOGIC CYTOPTHOLOGY CK5/6 in Effusions No Difference etween Mesothelioma and Pulmonary and Nonpulmonary denocarcinoma nnika Dejmek, M.D., Ph.D. Objective To test the performance of CK5/6 for theMore information
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014More information
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation inMore information
For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleuralMore information
American Society for Investigative Pathology Sunday, March 21, 2010
American Society for Investigative Pathology Sunday, March 21, 2010 Helpful Markers for Diagnosis and Prognosis: What and When Mesothelioma Versus Carcinoma: Tempest in a Pleural Teapot? Jeffrey L. Myers,More information
Malignant Mesothelioma Electron Microscopy
33 Malignant Mesothelioma Electron Microscopy Raoul Fresco In spite of recent advances in immunocytochemistry, electron microscopy continues to be the gold standard for the differential diagnosis of mesotheliomaMore information
Materials and Methods. Results
Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,More information
Introduction Objective Methods Results Conclusion
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),More information
MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "ImageMore information
H istochem istry in the Diagnosis o f M alignant M esotheliom a *
A n n a l s o f C l i n i c a l L a b o r a t o r y S c i e n c e, Vol. 3, No. 3 Copyright 1973, Institute for Clinical Science H istochem istry in the Diagnosis o f M alignant M esotheliom a * MILTONMore information
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%More information
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Assunta De Rienzo, Ph.D. 1, Robert W. Cook, Ph.D. 2,More information
PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition email@example.com September 23, 2010 Screening: 3 tests for PCa A good screeningMore information
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin)
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin) Product Code: NCL-L-CD141 Leica Biosystems Newcastle Ltd Balliol Business Park West Benton Lane Newcastle Upon Tyne NE12 8EW United KingdomMore information
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of theMore information
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developingMore information
Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma
Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma Based on AJCC/UICC TNM, 7th edition Protocol web posting date: February 1, 2011 Procedures Resection AuthorsMore information
Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,More information
BRIEF REPORTS. Introduction
BRIEF REPORTS WT1, Monoclonal CEA, TTF1, and CA125 Antibodies in the Differential Diagnosis of Lung, Breast, and Ovarian Adenocarcinomas in Serous Effusions Weijian Zhu, M.D., Ph.D. and Claire W. Michael,More information
Malignant pleural mesothelioma: outcome of limited surgical management
Interactive Cardiovascular and Thoracic Surgery 2 (2003) 30 34 Institutional review Thoracic general Malignant pleural mesothelioma: outcome of limited surgical management Peter G. Phillips a, George AsimakopoulosMore information
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIACMore information
Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimentalMore information
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland DiagnosticMore information
The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericyticMore information
Lung Cancer 70 (2010) 43 50. Contents lists available at ScienceDirect. Lung Cancer. journal homepage: www.elsevier.
Lung Cancer 70 (2010) 43 50 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan Tissue and serum EGFR as prognostic factors in malignant pleural mesotheliomaMore information
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e ChirurgiaMore information
Lymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma
Anatomic Pathology / LYMPHOHISTIOCYTOID MESOTHELIOMA Lymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma Hasan S. Khalidi, MD, 1 L. Jeffrey Medeiros, MD,More information
Male. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per CapitaMore information
Malignant Mesothelioma in Body Fluids - with Special Reference to Differential Diagnosis from Metastatic Adenocarcinoma -
The Korean Journal of Pathology 2009; 43: 458-66 DOI: 10.4132/KoreanJPathol.2009.43.5.458 Malignant Mesothelioma in Body Fluids - with Special Reference to Differential Diagnosis from Metastatic AdenocarcinomaMore information
A succesfull case of HIPEC in a peritoneal mesothelioma patient
A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹PernambucoMore information
Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma
36 Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma Amy Powers and Michele Carbone Synovial sarcomas (SSs) are soft tissue tumors that occur primarily in adolescentsMore information
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort inMore information
H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of MarylandMore information
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesotheliomaMore information
A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management
A Gene Expression Test to Predict Prostate Cancer Aggressiveness Use Prolaris as a guide in your medical and surgical management What is Prolaris? A direct molecular measure of prostate cancer tumor biologyMore information
Metastatic Lobular Carcinoma of the Breast Presenting as a Frontal Scalp Mass and
Metastatic Lobular Carcinoma of the Breast Presenting as a Frontal Scalp Mass and Masquerading as Lymphoma: A Potential Pitfall in Aspiration Cytology Lauren Altman 1, Summer Student; Raptis George 2,More information
BREAST CANCER IN YOUNG AGE ( 40 YEARS): THE UNIVERSITY OF TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical CenterMore information
ORIGINAL ARTICLE PNL2 MELANOCYTIC MARKER IN IMMUNOHISTOCHEMICAL EVALUATION OF PRIMARY MUCOSAL MELANOMA OF THE HEAD AND NECK Luc G. Morris, MD, 1 Yong Hannah Wen, MD, PhD, 2 Daisuke Nonaka, MD, 2 Mark D.More information
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocationsMore information
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skalMore information
Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (email@example.com) Uma R Chandran (firstname.lastname@example.com)More information
Activity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) isMore information
D2-40 and calretinin a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation
& 2007 USCAP, Inc All rights reserved 0893-3952/07 $30.00 www.modernpathology.org D2-40 and calretinin a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiationMore information
Primary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very lowMore information
Supplementary Online Content
Supplementary Online Content Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to Surgery and Breast Cancer Survival in the United States. JAMA Oncology. Published online December 10, 2015. doi:10.1001/jamaoncol.2015.4508.More information


text:
Skip the Lines Today & Give a Climate-Friendly Gift
Friday, 26 November 2010
You can shop at home (or at your computer) and give a gift that also helps the climate. Check out Carbonfund.org's 2010 Holiday Gifts for individuals and businesses. You'll find fun and practical gifts as well as stocking stuffers that support important climate projects. Plus, get a FREE Carbonfund.org grocery tote bag for gift purchases of $30 or more. Or, do more shopping and get two free totes for $50 or more. Click here to start shopping!
Written by Harrison Walford


text:
Channing Tatum has closed the deal to play superhero Gambit, despite rumors this week that he was leaving the role for other options.
Variety reports that Channing Tatum is officially on board with the project which will see the cajun mutant Gambit in his own film. The character has been a member of the X-Men in the comic book series.
According to Variety, Channing Tatum has been attached to the Gambit project as both a producer and actor for some time. The magazine notes that Channing Tatum appeared at the Fox X-Men panel at this year's San Diego Comic-Con.
Variety reports that while the deal has been signed, the exact extent to which Channing Tatum will be involved has yet to be announced.
The Hollywood Reporter reports the negotiations between Fox and Channing Tatum had hit a snag, but added that such back-and-forth deals are common in major motion picture contracts.
According to The Hollywood Reporter, Fox wants the Gambit character to be an anchor, meaning he would star in his own movies as well as in ensemble films. This mean Channing Tatum would be committed much like the way Hugh Jackman has played the famous mutant X-Man Wolverine both in solo and group films. Jackman, who indicated that his next time appearing as Wolverine will be his last, has been playing the part for 15 years.
The Hollywood Reporter cites a source close to the negotiations who says that backend compensation was one of the issues that Fox and Channing Tatum had to work out.
In addition to Channing Tatum, Gambit has Rupert Wyatt to direct. He previously worked on Fox's Rise of the Planet of the Apes. The script for Gambit was written by Josh Zetumer, based on a treatment by Chris Claremont, who was one of the co-creators of the Gambit character.
News that Channing Tatum is not leaving the film will likely be met with mixed reactions from fans. As reported by the Inquisitr, some fans were actually excited to hear that he was leaving the project. One of the reported rumors was that Channing Tatum was going to bail on the superhero project in favor of a supernatural one. Some sources said Channing Tatum was leaving Gambit to take a part in one of the upcoming Ghostbuster reboots.
If everything goes according to plan, Channing Tatum will take the screen as Gambit in October, 2016.
[Image by Lisa Maree Williams via Getty Images]


text: Hello guys i've done this a month ago in the lounge and after seeing Unzero's thread I decided to start doing it again. I will bookmark your sites using senuke. First of I can't stress this enough ||||DO NOT POST YOUR SITE URL OR NICHE IN THE THREAD||||| To get free bookmarking you have to PM me with: Site URL Title - Spinned Preferably(I am not going to spin it for you so you have to send me spinned one) Description Tags Up to THREE sites or URLS per person. Requirements = Atleast 20 Posts. Don't pm me if you have less than 20 posts or registed in August Why I am doing this ? Well I got pretty good feedback for my senuke coaching so I decided to build up a little feedback for linkbuilding since I'll be posting a thread in the bst section in a few days selling ALOT of stuff. When I finish the bookmarking I expect you to leave me Itrader with your comment(either positive or negative depending on your opionion) and maybe a thanks ? Again DONT POST YOUR SITE URL HERE.


text:
Regular price
After Your Purchase a Dietitian Will Contact you within 24 Hours To Customize and Set Up Your Program. Only 90 Seconds to Heat and Eat, No Fuss, NO Mess. Fully Customized Prepared Healthy Meals Delivered Daily. 3 Meals and 2 Snacks, Monday thru Friday or 7 days a week you will receive a fresh days meals daily. Sign up for our 31 day program for the low rate of $37.95 per day and our dietitian will contact you to set up your program. We will customize your program to suit you goals and needs. We will create a program to suit your busy lifestyle. If you want to speak to a human or have question or issues signing up you can reach us at 866-961-9663.
Thank you
Disclaimer: Please take note that no statement regarding the Companys products has been evaluated by the Food and Drug Administrations. The Companys products are not intended to cure, prevent, diagnose or treat any disease nor are they intended to treat specific medical conditions or health problems. Zone Culinaire LLC is not associated with Dr. Sears or his Zone trademarks. Moreover, the Companys programming is not meant as a substitute for medical care from a medical.


text:
DescriptionEleaf iStick TC100W Box Mod
The iStick TC100W by Eleaf builds upon the success of the previous iStick devices. The iStick TC100W can fire up to 100 watts and now features the ability to fire Nickel 200, Titanium, and 316 Stainless Steel wire in temperature control mode.
The iStick TC100W features an ergonomic design with a hidden, rigid side button for a better grip when vaping. The fire button is located behind the battery cover, similar to the fire button on the Smoktech XCube (squeeze the device to fire it).
The iStick TC100W features a fire button lock which is conveniently located at the top of the device to protect the device from unintentional firing. The device also features two magnetic battery covers for easy battery replacement. The iStick TC100W may also be upgradeable through future firmware updates via Micro USB.
The iStick TC100W features the ability to use a single or dual high amp 18650 battery configuration (Sold separately). Depending on your preferences you can vape up to 75W using a single battery or 100W using two batteries.
Please use the same type of battery and maintain the same amount of battery life when using a dual battery configuration.
We recommend using an external charger for your batteries for optimal and balanced charging.
Features and Specs:
- Stainless Steel 510 Threads
- Dimensions: 3-3/4" x 2" x 7/8"
- Variable Wattage: 1.0W - 100W
- Temperature Control : Nickel 200/ Titanium / 316 Stainless Steel
- Temperature Control Range: 100 - 315C / 200 - 600F
- Resistance: 0.1 - 3.5ohm for Variable Wattage
- Resistance: 0.05 - 1.5ohm for Temperature Control
- Magnetized Battery Covers
- Requires a Single or Dual 18650 High Amp Battery Configuration (Sold Separately)
- Conveniently Located Fire Button Lock/Unlock Function
- Hidden Fire Button
- Stealth Functionality
- OLED Display Screen
- Temperature Alert
- Low Voltage Protection
- Temperature Protection
- Atomizer Protection
- Short Circuit Protection
- Micro USB Port for Charging or Firmware Updates
The Eleaf iStick TC100W will include a 30 day Limited Warranty against any manufacturing defects from the date of delivery. Scratches and discoloration from regular use is considered normal wear and tear and is not covered by warranty.
NOTE: Use special caution when working with Li-ion cells, they are very sensitive to charging characteristics and may explode or burn if mishandled. Make sure the user has enough knowledge of Li-Ion rechargeable batteries in charging, discharging and assembly before use. Always charge in/on a fire-proof surface. Never leave charging batteries unattended. We are not responsible for damage if there is any modification of the batteries/chargers in any form or shape (including pack making). We are not responsible for any damage caused by misuse or mishandling of Li-Ion batteries and chargers.
This device should only be used with rechargeable Lithium Ion IMR batteries with an amp limit of 20A or higher. Using other batteries can be potentially hazardous.
myvaporstore.com will not be held responsible or liable for any injury, damage, or defect, permanent or temporary that may be caused by the improper use of a LI-ION battery. Please have a basic understanding of the batteries you are using and how to care for them properly.
Please note: Temperature control requires the use of nickel, titanium, or stainless coils.
You May Also Like ...
Price: $34.95
Price: $81.27
Sale Price: $59.95
Sale Price: $59.95
Price: $69.99
Sale Price: $39.95
Sale Price: $39.95
Price: $169.95
Sale Price: $139.00
Sale Price: $139.00
Price: $11.95
Price: $3.50
Price: $21.95
Sale Price: $19.95
Sale Price: $19.95
Price: $64.95
Sale Price: $43.95
Sale Price: $43.95
Price: $39.99
Sale Price: $27.95
Sale Price: $27.95
Price: $99.95
Sale Price: $64.95
Sale Price: $64.95
Browse for more products in the same category as this item:MODS & PVs
MODS & PVs -> 30W - 80W Devices
MODS & PVs -> 100W - 200W Devices
MODS & PVs -> Box Mods
MODS & PVs -> Dual Battery
MODS & PVs -> Temperature Control
New Arrivals


text:
I believe that the infinity of the universe is actually storage space for the heaps of astonishing love taking form during every moment of parenthood. The wealth of newly born emotion that is constantly taking unseen shape has to go somewhere- and that is where the vast space of the universe comes in. To that end, before Finn came into our lives, if I started thinking too much about how the sky goes on forever I felt as if my brain just might explode from the absolute incomprehension of it. I would go around in circles over that the idea that if the sky did in fact end, there would have to be something beyond the stopping point so in fact it would never really ever end. With the universe being so unimaginably huge, in order to keep my brain from exploding and my mind from reeling completely out of control, I would anxiously come back to earth where, now, I sit on the grass of Observatory Park and I look down at that tiny beautiful boy. Finn Leonard. And as I look into his blue brown eyes I realize that I've made an epic discovery. The never ending quality of the universe is mirrored in the ever burgeoning love I am draped with every time Finn grins at me. What I feel for every ounce of that gorgeous, amazing, giggling little boy is truly something that has form and although I cannot touch it nor can I put the appropriate words to it, the strength of it is such that if the universe weren't quite so big I'm not sure if it could contain everything that I'm feeling. And I feel like the luckiest person in the world that I get to spend my whole life with him and his father. And I realize that rather than the enormity of it all making me feel as if I'm going crazy, it is in fact what keeps me quite sane because Finn and I get to be a part of it together and the vastness of it all is suddenly just fine. So once again I've come to believe that the infinity of the universe is actually storage space for the heaps of astonishing love taking shape during every moment of parenthood.
If you enjoyed this essay, please consider making a tax-deductible contribution to This I Believe, Inc.